# Adebrelimab

Source: https://onco.cc/drugs/adebrelimab/  
OnCo record `adebrelimab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Adebrelimab is Hengrui's PD-L1 antibody, approved in China for first-line extensive-stage small cell lung cancer on the CAPSTONE-1 trial.

## Summary

CAPSTONE-1 randomised 462 patients with extensive-stage small cell lung cancer to adebrelimab or placebo with carboplatin and etoposide: median overall survival 15.3 versus 12.8 months (hazard ratio 0.72), among the largest survival gains reported for a PD-L1 antibody in this disease. The NMPA approved the combination in March 2023. Hengrui is testing adebrelimab in limited-stage disease after chemoradiotherapy and with its own ADCs.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-10
- Tags: china
- Brand: Arelili
- Code: SHR-1316
- Modality: Monoclonal antibody (anti-PD-L1, humanised IgG4)
- Mechanism: Humanised anti-PD-L1 IgG4 antibody blocking PD-L1 binding to PD-1 and B7-1.
- Approvals: China 2023: First-line extensive-stage small cell lung cancer with carboplatin and etoposide (CAPSTONE-1)

## Sources

- Jiangsu Hengrui Pharmaceuticals: https://www.hengrui.com/en/
- CAPSTONE-1 (Lancet Oncol 2022): https://doi.org/10.1016/S1470-2045(22)00224-8
- NMPA (National Medical Products Administration): https://www.nmpa.gov.cn

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [CD80 (B7-1)](https://onco.cc/targets/cd80/), [PD-L1](https://onco.cc/targets/pdl1/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)
- pathways: [PD-1 / PD-L1 immune checkpoint & T-cell activation](https://onco.cc/pathways/pd1-checkpoint/)
- terms: [Limited-stage vs extensive-stage (small-cell lung cancer)](https://onco.cc/terms/limited-extensive-stage/)
- trials: [A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer](https://onco.cc/trials/nct06840002/), [A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer](https://onco.cc/trials/nct06778031/), [A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer](https://onco.cc/trials/nct07111832/), [A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer](https://onco.cc/trials/nct07736612/), [A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06474455/), [A Phase II Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC](https://onco.cc/trials/nct06177925/), [A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer](https://onco.cc/trials/nct07241767/), [A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour](https://onco.cc/trials/nct06915142/), [A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC](https://onco.cc/trials/nct07798947/), [A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamo](https://onco.cc/trials/nct07824882/), [A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer](https://onco.cc/trials/nct07071714/), [A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients](https://onco.cc/trials/nct06335355/), [A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the](https://onco.cc/trials/nct07168200/), [A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer](https://onco.cc/trials/nct07135544/), [A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Pat](https://onco.cc/trials/nct07822542/), [A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation](https://onco.cc/trials/nct06385678/), [A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.](https://onco.cc/trials/nct06620848/), [A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC](https://onco.cc/trials/nct06754930/), [A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors](https://onco.cc/trials/nct06703177/), [A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors](https://onco.cc/trials/nct07229586/), [A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06589778/), [A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct07229729/), [A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer](https://onco.cc/trials/nct07679360/), [A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer](https://onco.cc/trials/nct07110571/), [A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct05482568/), [A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors](https://onco.cc/trials/nct07028281/), [A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors](https://onco.cc/trials/nct07268040/), [A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma](https://onco.cc/trials/nct07393542/), [A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer](https://onco.cc/trials/nct07059221/), [A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer](https://onco.cc/trials/nct06474468/), [A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct06512051/), [A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma](https://onco.cc/trials/nct06639347/), [A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors](https://onco.cc/trials/nct06417554/), [Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cance](https://onco.cc/trials/nct06531278/), [Adebrelimab + Apatinib in SCLC Maintenance Therapy](https://onco.cc/trials/nct06475209/), [Adebrelimab and Chidamide for Pancreatic Cancer](https://onco.cc/trials/nct06584227/), [Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer](https://onco.cc/trials/nct06916975/), [Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC](https://onco.cc/trials/nct06672133/), [Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer](https://onco.cc/trials/nct06177522/), [Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07392541/), [Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions](https://onco.cc/trials/nct07230301/), [Adebrelimab Plus S-1 for Resected Cholangiocarcinoma](https://onco.cc/trials/nct07561775/), [Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer](https://onco.cc/trials/nct07569679/), [An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer](https://onco.cc/trials/nct07061210/), [An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors](https://onco.cc/trials/nct07806058/), [An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies](https://onco.cc/trials/nct07668453/), [CAPSTONE-1](https://onco.cc/trials/capstone-1/), [Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer](https://onco.cc/trials/nct06280508/), [Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC](https://onco.cc/trials/nct06037655/), [Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer](https://onco.cc/trials/nct07522151/), [Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer](https://onco.cc/trials/nct07827053/), [Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)](https://onco.cc/trials/nct06879145/), [Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer](https://onco.cc/trials/nct04516681/), [Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsate](https://onco.cc/trials/nct06282445/), [Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer](https://onco.cc/trials/nct06229067/), [Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma](https://onco.cc/trials/nct06427239/), [Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer](https://onco.cc/trials/nct06547736/), [HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer](https://onco.cc/trials/nct06389500/), [HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors](https://onco.cc/trials/nct07296341/), [HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer](https://onco.cc/trials/nct07131514/), [Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer](https://onco.cc/trials/nct07718490/), [Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Ext](https://onco.cc/trials/nct06610734/), [Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer](https://onco.cc/trials/nct05671822/), [Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors](https://onco.cc/trials/nct07073534/), [Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic P](https://onco.cc/trials/nct06454448/), [Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy fo](https://onco.cc/trials/nct06771609/), [Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer](https://onco.cc/trials/nct07670273/), [Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer](https://onco.cc/trials/nct07704177/), [Reverse Triple Negative Immune Resistant Breast Cancer](https://onco.cc/trials/nct05076682/), [SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer](https://onco.cc/trials/nct06373133/), [SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer](https://onco.cc/trials/nct06465563/), [SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer](https://onco.cc/trials/nct06819319/), [Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC](https://onco.cc/trials/nct06165900/), [Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer](https://onco.cc/trials/nct06599775/), [Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer](https://onco.cc/trials/nct06222879/), [Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer](https://onco.cc/trials/nct06247956/), [The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct07704645/), [The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra](https://onco.cc/trials/nct06266832/)
- people: [Ying Cheng](https://onco.cc/people/cheng-ying/)
- institutions: [Jilin Cancer Hospital](https://onco.cc/institutions/jilin-cancer-hospital/)

---
JSON: https://onco.cc/api/v1/entities/adebrelimab.json